{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:53:57Z","timestamp":1789055637158,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bneo.2025.100175","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:30:03Z","timestamp":1761377403000},"page":"100175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-4246","authenticated-orcid":false,"given":"Akhil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-5717","authenticated-orcid":false,"given":"Caitlin R.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres E.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2025.100175_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ajh.24679","article-title":"Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia","volume":"92","author":"Hu","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2025.100175_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/aqae075","article-title":"Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family-negative T-prolymphocytic leukemia","author":"Fang","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"14","key":"10.1016\/j.bneo.2025.100175_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.2019000402","article-title":"Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia","volume":"134","author":"Staber","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100175_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CLM.2005.n.051","article-title":"T-cell prolymphocytic leukemia: a single-institution experience","volume":"6","author":"Ravandi","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"10.1016\/j.bneo.2025.100175_bib5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100175_bib6","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.bneo.2025.100175_bib7","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100175_bib8","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jtct.2022.01.017","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: a contemporary analysis from the Center for International Blood and Marrow Transplant Research","volume":"28","author":"Murthy","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100175_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2024-198075","article-title":"Long-term outcomes of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"144","author":"Drozd-Sokolowska","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100175_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100175_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.13952","article-title":"Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia","volume":"173","author":"L\u00f3pez","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100175_bib12","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/cancers11121833","article-title":"JAK\/STAT-activating genomic alterations are a hallmark of T-PLL","volume":"11","author":"Wahnschaffe","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bneo.2025.100175_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41467-017-02688-6","article-title":"Actionable perturbations of damage responses by TCL1\/ATM and epigenetic lesions form the basis of T-PLL","volume":"9","author":"Schrader","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.bneo.2025.100175_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Bellanger","year":"2014","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.bneo.2025.100175_bib15","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/bloodadvances.2017010470","article-title":"T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)","volume":"1","author":"Li","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2025.100175_bib16","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/10428194.2019.1594220","article-title":"Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1\/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation","volume":"60","author":"Gomez-Arteaga","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.bneo.2025.100175_bib17","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood.V126.23.5486.5486","article-title":"Refractory T-cell prolymphocytic leukemia with JAK3 mutation: in vitro and clinical synergy of tofacitinib and ruxolitinib","volume":"126","author":"Wei","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2025.100175_bib18","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood.2020007303","article-title":"BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia","volume":"137","author":"Herbaux","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100175_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2237342","article-title":"Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia","volume":"28","author":"Brothers","year":"2023","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.bneo.2025.100175_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00019","article-title":"Genomic profiling of T-cell neoplasms reveals frequent JAK1 and JAK3 mutations with clonal evasion from targeted therapies","volume":"2018","author":"Greenplate","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bneo.2025.100175_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173505","article-title":"Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"885","author":"Covington","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100175_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2025.100175_bib23","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(21)00367-7","article-title":"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial","volume":"9","author":"Zeiser","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100175_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100175_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jcph.2202","article-title":"Itacitinib population pharmacokinetics and exposure-response in patients with acute graft-versus-host disease","volume":"63","author":"Chen","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"10.1016\/j.bneo.2025.100175_bib26","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100175_bib27","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/annonc\/mdx163","article-title":"Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)","volume":"28","author":"Jain","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100175_bib28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood-2024-194242","article-title":"Survival and therapeutic outcomes in T-cell prolymphocytic leukemia (T-PLL): a collaborative multi-center study cohort","volume":"144","author":"Braunstein","year":"2024","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:48:07Z","timestamp":1771465687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2950328025001104"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100175","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100175"}}